Artelo says preclinical osteoarthritis study shows ART26.12 matches naproxen pain relief with less gastric damage

Artelo Biosciences reported nonclinical osteoarthritis data showing oral ART26.12 reduced pain behaviors over 4 weeks with efficacy comparable to naproxen.

Preclinical results showed significantly less stomach tissue damage versus naproxen, signaling a potentially improved gastrointestinal safety profile for chronic use.

Artelo plans a multiple ascending repeat-dose clinical study in healthy volunteers, with enrollment expected to start in Q4.